Immuneering Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on October 29, 2026, covering financial results and operational updates for the third quarter.

Key Highlights

  • Share count: As of October 23, 2026, Immuneering had 64,763,155 shares of Class A common stock issued and outstanding, and 0 shares of Class B common stock.
  • Filing period: The quarterly report covers the three and nine months ended September 30, 2026.
  • Company classification: Immuneering is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Lead program: The filing references an ongoing Phase 1/2a clinical trial of atebimetinib (also referred to as IMM-1-104) and a MAPKeeper 301 registrational trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Immuneering's Third-Quarter 2026 Quarterly Report: Key Disclosures

Immuneering Corporation (NASDAQ:IMRX), a Delaware-incorporated biopharmaceutical company headquartered at 245 Main St., Second Floor, Cambridge, MA 02142, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, the company had 64,763,155 shares of Class A common stock, par value $0.001 per share, issued and outstanding as of October 23, 2026, with zero shares of Class B common stock outstanding.

The filing confirmed that Immuneering's Class A common stock trades on The Nasdaq Global Market under the ticker symbol IMRX. The company reported it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically. Immuneering identified itself as a non-accelerated filer, a smaller reporting company, and an emerging growth company, and indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards.

The quarterly report includes condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, statements of operations for the three and nine months ended September 30, 2026 and 2025, and related cash flow statements. The filing notes the company's ongoing clinical programs, including its Phase 1/2a trial of atebimetinib and the MAPKeeper 301 registrational trial in first-line pancreatic cancer. The filing contains forward-looking statements, which, according to the company's own cautionary language, "are only predictions" and are subject to known and unknown risks and uncertainties described in the filing's Risk Factors and Management's Discussion and Analysis sections.

What Was Disclosed

Immuneering filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 64,763,155 Class A shares outstanding as of October 23, 2026, its smaller reporting company and emerging growth company status, and ongoing clinical trials for atebimetinib.